Shenzhen Salubris Pharmaceuticals Co., Ltd. (002294) Stock Recommendation | Score, Valuation, Technicals & Financial Trend

Score

Click here to find our call on this stock

Strong Sell

Sell

Hold

Buy

Strong Buy

Comparison

Company

Score

Quality

Valuation

Financial

Technical

Shenzhen Salubris Pharmaceuticals Co., Ltd.

Why is Shenzhen Salubris Pharmaceuticals Co., Ltd. ?

Poor long term growth as Net Sales has grown by an annual rate of 6.94% and Operating profit at 13.70% over the last 5 years

Flat results in Sep 25

INTEREST(HY) At CNY 9.84 MM has Grown at 19.89%
DEBT-EQUITY RATIO (HY) Highest at -14.75 %
INVENTORY TURNOVER RATIO(HY) Lowest at 2.22 times

With ROE of 7.28%, it has a fair valuation with a 7.92 Price to Book Value

Over the past year, while the stock has generated a return of 24.02%, its profits have fallen by -1.5%
At the current price, the company has a high dividend yield of 0.8

Real-Time Research Report

Verdict Report

How much should you hold?

Overall Portfolio exposure to Shenzhen Salubris Pharmaceuticals Co., Ltd. should be less than 10%
Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock

Is Shenzhen Salubris Pharmaceuticals Co., Ltd. for you?

High Risk, High Return

Absolute

Risk Adjusted

Volatility

Shenzhen Salubris Pharmaceuticals Co., Ltd.

18.39%

1.67

51.51%

China Shanghai Composite

24.7%

1.93

12.95%

Quality

Management Risk

Growth

Capital Structure

Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor

Value

Sales Growth (5y)

6.94%

EBIT Growth (5y)

13.70%

EBIT to Interest (avg)

32.71

Debt to EBITDA (avg)

Net Debt to Equity (avg)

-0.19

Sales to Capital Employed (avg)

0.45

Tax Ratio

3.14%

Dividend Payout Ratio

92.59%

Pledged Shares

Institutional Holding

ROCE (avg)

7.91%

ROE (avg)

7.07%

Valuation

Valuation Scorecard

Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors

Factor

Value

P/E Ratio

109

Industry P/E

Price to Book Value

7.92

EV to EBIT

127.78

EV to EBITDA

69.67

EV to Capital Employed

10.25

EV to Sales

16.18

PEG Ratio

Dividend Yield

0.82%

ROCE (Latest)

8.02%

ROE (Latest)

7.28%

Technicals

Technical key factors

Indicator

Weekly

Monthly

MACD

Mildly Bearish

RSI

No Signal

Bollinger Bands

Bearish

Mildly Bullish

Moving Averages

Mildly Bullish (Daily)

KST

Bullish

Dow Theory

Mildly Bearish

Mildly Bullish

OBV

Mildly Bearish

Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned

Technical Movement

Analyse All Technical Factors

Financial Trend

Financial Trend Scorecard

Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

8What is working for the Company

ROCE(HY)

Highest at 7.74%

NET SALES(Q)

Highest at CNY 1,110.33 MM

RAW MATERIAL COST(Y)

Fallen by -4.25% (YoY

PRE-TAX PROFIT(Q)

Highest at CNY 234.43 MM

NET PROFIT(Q)

Highest at CNY 213.84 MM

EPS(Q)

Highest at CNY 0.19

-8What is not working for the Company

INTEREST(HY)

At CNY 9.84 MM has Grown at 19.89%

DEBT-EQUITY RATIO (HY)

Highest at -14.75 %

INVENTORY TURNOVER RATIO(HY)

Lowest at 2.22 times

Here's what is working for Shenzhen Salubris Pharmaceuticals Co., Ltd.

Net Sales

Highest at CNY 1,110.33 MM and Grown

In each period in the last five periods

MOJO Watch

Near term sales trend is very positive

Net Sales (CNY MM)

Pre-Tax Profit

Highest at CNY 234.43 MM

in the last five periods

MOJO Watch

Near term Pre-Tax Profit trend is positive

Pre-Tax Profit (CNY MM)

Net Profit

Highest at CNY 213.84 MM

in the last five periods

MOJO Watch

Near term Net Profit trend is positive

Net Profit (CNY MM)

EPS

Highest at CNY 0.19

in the last five periods

MOJO Watch

Increasing profitability; company has created higher earnings for shareholders

EPS (CNY)

Raw Material Cost

Fallen by -4.25% (YoY)

MOJO Watch

The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Here's what is not working for Shenzhen Salubris Pharmaceuticals Co., Ltd.

Interest

At CNY 9.84 MM has Grown at 19.89%

over previous Semi-Annual period

MOJO Watch

Rising interest cost signifies increased borrowings

Interest Paid (CNY MM)

Debt-Equity Ratio

Highest at -14.75 %

in the last five Semi-Annual periods

MOJO Watch

The company is borrowing more to fund its operations; it's liquidity situation may be stressed

Debt-Equity Ratio

Inventory Turnover Ratio

Lowest at 2.22 times

in the last five Semi-Annual periods

MOJO Watch

Company's pace of selling inventory has slowed

Inventory Turnover Ratio